

APAS® INDEPENDENCE SCIENTIFIC DATA PRESENTED AT ECCMID

ECCMID is the largest global conference for clinical microbiology, held online, 9 - 12 July 2021

Adelaide, Australia, 09 July 2021: Australian medical technology company LBT Innovations Limited (ASX: LBT) (**LBT or the Company**), a leader in medical technology automation using artificial intelligence, is pleased to announce the presentation of data from five clinical studies featuring the APAS® Independence at the European Congress of Clinical Microbiology and Infectious Diseases (**ECCMID**) to be held online from 9 - 12 July 2021.

Key Points:

- **First published data demonstrating the use of APAS® Independence for early reading of culture plates**
- **First published data demonstrating improved screening of MRSA vs Total Laboratory Automation**
- **Collectively the largest body of scientific data supporting key clinical benefits of the APAS® Independence**
- **Five poster publications featuring data on the APAS® Independence will be presented at ECCMID 2021**
- **Clinical studies from Labor Dr Wisplinghoff (DE), Health Services Laboratory (UK) and SA Pathology (AU)**

The annual ECCMID conference is the world's premier conference for clinical microbiology and infectious diseases. The 2021 ECCMID conference is being held online and will bring together leading experts to present the latest findings and developments in the industry. This year, five poster presentations have been accepted for display at the ECCMID conference, showcasing five different clinical studies using LBT's APAS® technology. Importantly, this represents the largest body of scientific data featuring the APAS® Independence to be presented globally and presentations such as these are critical for raising clinical awareness and underpinning the robustness of the technology.

The posters to be presented include clinical data from recent evaluations of the APAS® Independence completed at the Health Services Laboratory, UK and SA Pathology, Australia as well as two studies from the Company's key opinion leader in Germany, Labor Dr Wisplinghoff. The data generated provides valuable clinical evidence to support the product claims for the APAS® Independence. Importantly, the study completed and presented by SA Pathology, provides the first direct comparison of the APAS® Independence with a total laboratory automation system. In this study, the APAS® Independence demonstrated an improved sensitivity for the screening of MRSA culture plates at 48 hours when compared to the Becton Dickinson Kiestra system.

A further poster will be presented demonstrating the use of the APAS® technology to read culture plates much earlier than currently recommended. This is an exciting new technology development in response to industry demands that may have the potential to greatly accelerate the time to make a diagnosis when running infection control screening, such as testing for Vancomycin Resistant Enterococci (VRE) or Methicillin Resistant *Staphylococcus aureus* (MRSA or Golden Staph).

Details of Posters Presented on APAS® Independence

All five posters presented at the conference, along with interviews with each of the presenting authors, will be made available on the Company website under the Scientific Library section once the conference is over on 13 July 2021.

<https://lbtinnovations.com/products/scientific-library/>

Comparison of MRSA plate reading methods: APAS® Independence (Artificial intelligence), plate-in-hand and Kiestra™ (digital reads)

Casey Moore¹, Manuel Morales², Judith Holds¹, Kathy Diep¹, Steven Giglio²

1. SA Pathology, 2. LBT Innovations

Validation of APAS® Independence (CCS) artificial intelligence (AI) algorithms to detect MRSA in a routine setup

Sophie Krienke¹, Angela Nowag¹, Hilmar Wisplinghoff¹, Steve Giglio², Sarah Wirth¹, Nathalie Jazmati¹

1. Labor Dr Wisplinghoff, 2. LBT Innovations

Evaluation of the use of artificial intelligence for the detection of VRE using two different agar types

Angela Nowag¹, Hilmar Wisplinghoff¹, Xenia Quante¹, Steve Giglio², Sarah Wirth¹, Bärbel Pohl¹, Nathalie Jazmati¹

1. Labor Dr Wisplinghoff, 2. LBT Innovations

Evaluation of an automated culture plate reading instrument for MRSA culture screening

Alan Williams¹, Alan Spratt¹

1. Health Services Laboratory

Introducing artificial intelligence for early Vancomycin Resistant Enterococci culture reads with APAS®

Manuel Morales¹, Bianca De Young¹, Ryan Green¹, Hilmar Wisplinghoff², Steven Giglio¹

1. Clever Culture Systems, 2. Labor Dr Wisplinghoff

LBT Scientific Director, Dr Steven Giglio said:

“It is really exciting to see such a large body of clinical data presented at the ECCMID conference, our largest to date and just as importantly from a number of labs across the globe. The presentation of independent clinical data at the largest global conference in our industry is extremely important as it provides reference points for customers and clinicians when evaluating the APAS® Independence. Application of the APAS® technology to early culture reads has the potential to further disrupt the current application of testing in clinical laboratories, with the potential to improve patient care through faster turnaround of results.”

Approved for release by the Chair of the LBT Board.

– ENDS –

About LBT Innovations

LBT Innovations (LBT) improves patient outcomes by making healthcare more efficient. Based in Adelaide, South Australia, the Company has a history of developing world leading products in microbiology automation. Its first product, MicroStreak®, was a global first in the automation of the culture plate streaking process. The Company's second product, the Automated Plate Assessment System (APAS®) is being commercialised through LBT's 50% owned joint venture company Clever Culture Systems AG (CCS) with Hettich Holding Beteiligungs- und Verwaltungs-GmbH. Beckman Coulter have also been appointed as Marketing Agent in Europe to assist in facilitating sales. The APAS® instrument is based upon LBT's intelligent imaging and machine learning software and remains the only US FDA-cleared artificial intelligence technology for automated imaging, analysis and interpretation of culture plates following incubation.

CONTACTS

| LBT Innovations | Investor Enquiries |
|---|---|
| Brent Barnes Chief Executive Officer & Managing Director Tel: +61 8 8227 1555 E: info@lbtinnovations.com | David Allen / John Granger Hawkesbury Partners Tel: +61 2 9103 9494 E: jgranger@hawkesburypartners.com |